SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Winfastorlose who wrote (1341524)2/7/2022 3:01:30 PM
From: Tenchusatsu  Respond to of 1582284
 
WFoL,
that means companies like TEVA and others out of India, for example, can make and sell the generic forms much cheaper. As they already do.
So what? Even off-patent drugs can be profitable when sold here.

You antivaxxers, for example, would LOVE to pay $2-$10 a dose for Ivermectin. That in itself is a huge source of potential revenue.

Tenchusatsu


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News